fort myers slot machines
TORONTO, ONTARIO, Jul 2, 2003 (CCNMatthews via COMTEX) Biovail Corporation (NYSE, TSX: BVF) announced today that it has submitted a supplemental New Drug Application (sNDA) to the U. S. Food and Drug Administration (FDA for an angina indication for Cardizem(R) LA. Biovail launched Cardizem LA, a once-daily oral graded-release diltiazem formulation used in the treatment of hypertension, in the United States on April 2, 2003. Cardizem LA belongs to the family of medications referred to as Calcium Channel Blockers. Related Results Fort Lauderdale, Fla.-Based Drug Maker's Shares Increase.(Knight Ridder/Tribu... jackpot far far away does japan have gambling casinos bally cpu slot parts no deposit online casino free tournaments
